Feds 'Copped Out,' Says Analyst
Roche Trial Pending, Amgen Gets CMS' Word On Payouts
As Amgen Inc. gears up for its legal skirmish over Mircera, the erythropoietin stimulating agent (ESA) from F. Hoffmann-La Roche Ltd., the Centers for Medicare & Medicaid Services last week issued its edict on reimbursement for the class of drugs in oncology, including Amgen's and Epogen (epoetin alfa) and the second-generation product Aranesp (darbepoetin alfa). Both drugs are approved for anemia in cancer patients and in chronic kidney disease (CKD). (BioWorld Financial Watch)
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.